Truist initiated coverage of PTC Therapeutics (PTCT) with a Buy rating and $80 price target The potential launches of two drugs in coming months – sepiapterin for phenylketonuria and vatiquinone for Friedreichs’ ataxia – along with a “promising pipeline” borne out of PTC’s RNA modulation platform should more than offset Translarna’s “checkered past in DMD” and check “many of the boxes for a compelling biotech investment,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Buy Rating Backed by Promising Sepiapterin Launch and Robust Financial Outlook
- PTC Therapeutics price target raised to $60 from $58 at RBC Capital
- PTC Therapeutics: Promising Pipeline and Strategic Preparations Justify Buy Rating
- RBC Capital views FDA flexibility on another HD drug as positive for PTC’s ‘518
- PTC Therapeutics: Promising Drug Pipeline and Market Opportunities Justify Buy Rating